The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

With the validation of the SARS-CoV-2 mRNA vaccines on the global stage, mRNA vaccines and therapeutics are taking the front seat of many biopharma development pipelines. There is an ever-increasing ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

The mRNA vaccine drug development market presents growth opportunities through increased investment, diverse therapeutic applications, and scalable production demand. Key prospects include strategic ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

FARGO, N.D., May 1, 2023 /PRNewswire/ -- Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production ...

The "mRNA Synthesis Raw Materials - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA Synthesis Raw Materials was estimated at ...

Researchers develop a self-regulating mRNA medicine that adjusts protein production based on disease-related signals. A research team from The University of Osaka and Institute of Science Tokyo has ...